Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues

Purpose: This study examines cell surface ROR1 expression in human tumors and normal tissues. ROR1 is considered a promising target for cancer therapy due to putative tumor-specific expression, and multiple groups are developing antibodies and/or chimeric antigen receptor–modified T cells to target ROR1. On-target, off-tumor toxicity is a challenge for most nonmutated tumor antigens; however, prior studies suggest that ROR1 is absent on most normal tissues. Experimental Design: Our studies show that published antibodies lack sensitivity to detect endogenous levels of cell surface ROR1 by immunohistochemistry (IHC) in formalin-fixed, paraffin-embedded tissues. We developed a ROR1-specific monoclonal antibody (mAb) targeting the carboxy-terminus of ROR1 and evaluated its specificity and sensitivity in IHC. Results: The 6D4 mAb is a sensitive and specific reagent to detect cell surface ROR1 by IHC. The data show that ROR1 is homogenously expressed on a subset of ovarian cancer, triple-negative breast cancer, and lung adenocarcinomas. Contrary to previous findings, we found ROR1 is expressed on several normal tissues, including parathyroid; pancreatic islets; and regions of the esophagus, stomach, and duodenum. The 6D4 mAb recognizes rhesus ROR1, and ROR1 expression was similar in human and macaque tissues, suggesting that the macaque is a suitable model to evaluate safety of ROR1-targeted therapies. Conclusions: ROR1 is a promising immunotherapeutic target in many epithelial tumors; however, high cell surface ROR1 expression in multiple normal tissues raises concerns for on-target off-tumor toxicities. Clinical translation of ROR1-targeted therapies warrants careful monitoring of toxicities to normal organs and may require strategies to ensure patient safety. Clin Cancer Res; 23(12); 3061–71. ©2016 AACR.

[1]  Yu-Sun Chang,et al.  Expression of ROR1 has prognostic significance in triple negative breast cancer , 2016, Virchows Archiv.

[2]  Kole T. Roybal,et al.  Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits , 2016, Cell.

[3]  K. Yanagisawa,et al.  ROR1 sustains caveolae and survival signalling as a scaffold of cavin-1 and caveolin-1 , 2016, Nature Communications.

[4]  David Allman,et al.  Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. , 2015, Cancer discovery.

[5]  Wendell A. Lim,et al.  Remote control of therapeutic T cells through a small molecule–gated chimeric receptor , 2015, Science.

[6]  B. Kim,et al.  Expression of ROR1, pAkt, and pCREB in gastric adenocarcinoma. , 2015, Annals of diagnostic pathology.

[7]  M. Hochmair,et al.  Receptor tyrosine kinase expression of circulating tumor cells in small cell lung cancer , 2015, Oncoscience.

[8]  J. Bading,et al.  Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma , 2015, Clinical Cancer Research.

[9]  G. Widhopf,et al.  Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations , 2015, PloS one.

[10]  G. Widhopf,et al.  Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1. , 2015, Clinical lymphoma, myeloma & leukemia.

[11]  Y. Li,et al.  Silencing of Receptor Tyrosine Kinase ROR1 Inhibits Tumor-Cell Proliferation via PI3K/AKT/mTOR Signaling Pathway in Lung Adenocarcinoma , 2015, PloS one.

[12]  A. Österborg,et al.  The PI3K/AKT/mTOR pathway is involved in direct apoptosis of CLL cells induced by ROR1 monoclonal antibodies , 2015, British journal of haematology.

[13]  Emanuela M. Ghia,et al.  Ovarian cancer stem cells express ROR1, which can be targeted for anti–cancer-stem-cell therapy , 2014, Proceedings of the National Academy of Sciences.

[14]  S. Riddell,et al.  Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells , 2014, Cancer Immunology Research.

[15]  Jin Zhu,et al.  ROR1 expression correlated with poor clinical outcome in human ovarian cancer , 2014, Scientific Reports.

[16]  F. de Marinis,et al.  ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation. , 2014, Translational lung cancer research.

[17]  D. Torigian,et al.  Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies , 2013, Cancer Immunology Research.

[18]  S. Riddell,et al.  Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma , 2013, PloS one.

[19]  A. Österborg,et al.  The Tyrosine Kinase Receptor ROR1 Is Constitutively Phosphorylated in Chronic Lymphocytic Leukemia (CLL) Cells , 2013, PloS one.

[20]  S. Riddell,et al.  Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells , 2013, Clinical Cancer Research.

[21]  M. Jeddi-Tehrani,et al.  Inhibition of the Receptor Tyrosine Kinase ROR1 by Anti-ROR1 Monoclonal Antibodies and siRNA Induced Apoptosis of Melanoma Cells , 2013, PloS one.

[22]  S. Sleijfer,et al.  Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  L. Rassenti,et al.  Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis. , 2013, Cancer research.

[24]  Michel Sadelain,et al.  Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells , 2012, Nature Biotechnology.

[25]  J. Khan,et al.  Restricted Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Pediatric B-Lineage Acute Lymphoblastic Leukemia Suggests Targetability with Therapeutic Monoclonal Antibodies , 2012, PloS one.

[26]  Wendy Frankel,et al.  The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. , 2012, The American journal of pathology.

[27]  B. Druker,et al.  Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. , 2012, Cancer cell.

[28]  W. Wilson,et al.  Targeting malignant B cells with an immunotoxin against ROR1 , 2012, mAbs.

[29]  N. Cheung,et al.  ROR1 and ROR2 in Human Malignancies: Potentials for Targeted Therapy , 2012, Front. Oncol..

[30]  Tomoya Yamaguchi,et al.  NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. , 2012, Cancer cell.

[31]  J. Wang-Rodriguez,et al.  ROR1 Is Expressed in Human Breast Cancer and Associated with Enhanced Tumor-Cell Growth , 2012, PloS one.

[32]  M. Jeddi-Tehrani,et al.  Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells , 2012, Leukemia.

[33]  A. Kozubík,et al.  Post‐translational modifications regulate signalling by Ror1 , 2011, Acta physiologica.

[34]  Thomas M. Schmitt,et al.  The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. , 2010, Blood.

[35]  C. Rooney,et al.  Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b , 2010, Journal of immunotherapy.

[36]  T. Sayers,et al.  New flow cytometric assays for monitoring cell-mediated cytotoxicity , 2010, Expert review of vaccines.

[37]  S. Rosenberg,et al.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[38]  Jason S. Mitchell,et al.  Integrin function in T-cell homing to lymphoid and nonlymphoid sites: getting there and staying there. , 2009, Critical reviews in immunology.

[39]  C. Larsson,et al.  Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy , 2008, International journal of cancer.

[40]  E. Butcher,et al.  Environmental cues, dendritic cells and the programming of tissue-selective lymphocyte trafficking , 2008, Nature Immunology.

[41]  B. Engels,et al.  Enhanced functionality of T cell receptor-redirected T cells is defined by the transgene cassette , 2008, Journal of Molecular Medicine.

[42]  L. Rassenti,et al.  Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a , 2008, Proceedings of the National Academy of Sciences.

[43]  Adrian Wiestner,et al.  Unique Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Human B-Cell Chronic Lymphocytic Leukemia , 2008, Clinical Cancer Research.

[44]  I. Pastan,et al.  Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers , 2007, Clinical Cancer Research.

[45]  Si-young Song,et al.  Retinoic acid imprints gut-homing specificity on T cells. , 2004, Immunity.

[46]  F. Marincola,et al.  Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. , 2002, Human gene therapy.

[47]  Y. Tu,et al.  Gene Expression Profiling of B Cell Chronic Lymphocytic Leukemia Reveals a Homogeneous Phenotype Related to Memory B Cells , 2001, The Journal of experimental medicine.

[48]  David Botstein,et al.  Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia , 2001, The Journal of experimental medicine.

[49]  S. Ashton,et al.  Expression of the Ror1 and Ror2 receptor tyrosine kinase genes during mouse development , 2001, Development Genes and Evolution.

[50]  D. Pleasure,et al.  Human neural tissues express a truncated Ror1 receptor tyrosine kinase, lacking both extracellular and transmembrane domains. , 1996, Oncogene.